Type B insulin resistance developing during interferon-α therapy

Amanda L. Daniel, Josetta L. Houlihan, Janice Blum, James P. Walsh

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objective: To report a rare case of diabetes caused by type B insulin resistance due to development of insulin receptor autoantibodies during treatment of hepatitis C with interferon-α and ribavirin. Methods: Clinical and laboratory findings in the case are presented. The literature on type B insulin resistance and interferon-induced autoimmunity is reviewed. Results: A 55-year-old African American man with hepatitis C was treated with interferon and ribavirin. Eight months later, he presented with rapid onset of hyperglycemia, profound weakness, and weight loss. Severe hyperglycemia persisted despite insulin infusion rates as high as 125 U/h. The presence of insulin receptor autoantibodies was confirmed by immunoprecipitation of recombinant human insulin receptor with patient serum. Assays for autoantibodies to islet cell antigens and glutamic acid decarboxylase were negative. The interferon and ribavirin were discontinued. His insulin requirement spontaneously declined to low levels over a 6-month period. Two years after discharge of the patient, insulin receptor autoantibodies could no longer be demonstrated in his serum. He remains euglycemic and is no longer taking insulin. Conclusion: This case demonstrates that type B insulin resistance can occur as a complication of interferon- a therapy. To our knowledge, this is the first reported case in the United States of type B insulin resistance with development of insulin receptor autoantibodies during treatment with interferon-a. (Endocr Pract. 2009;15: 153-157).

Original languageEnglish
Pages (from-to)153-157
Number of pages5
JournalEndocrine Practice
Volume15
Issue number2
StatePublished - Mar 2009

Fingerprint

Interferons
Insulin Resistance
Autoantibodies
Insulin Receptor
Ribavirin
Insulin
Hepatitis C
Hyperglycemia
Therapeutics
Glutamate Decarboxylase
Patient Discharge
Serum
Autoimmunity
Islets of Langerhans
Immunoprecipitation
African Americans
B-insulin
Weight Loss
Antigens

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)

Cite this

Daniel, A. L., Houlihan, J. L., Blum, J., & Walsh, J. P. (2009). Type B insulin resistance developing during interferon-α therapy. Endocrine Practice, 15(2), 153-157.

Type B insulin resistance developing during interferon-α therapy. / Daniel, Amanda L.; Houlihan, Josetta L.; Blum, Janice; Walsh, James P.

In: Endocrine Practice, Vol. 15, No. 2, 03.2009, p. 153-157.

Research output: Contribution to journalArticle

Daniel, AL, Houlihan, JL, Blum, J & Walsh, JP 2009, 'Type B insulin resistance developing during interferon-α therapy', Endocrine Practice, vol. 15, no. 2, pp. 153-157.
Daniel AL, Houlihan JL, Blum J, Walsh JP. Type B insulin resistance developing during interferon-α therapy. Endocrine Practice. 2009 Mar;15(2):153-157.
Daniel, Amanda L. ; Houlihan, Josetta L. ; Blum, Janice ; Walsh, James P. / Type B insulin resistance developing during interferon-α therapy. In: Endocrine Practice. 2009 ; Vol. 15, No. 2. pp. 153-157.
@article{6341f0e0b37a44569f3982f0d19d6cca,
title = "Type B insulin resistance developing during interferon-α therapy",
abstract = "Objective: To report a rare case of diabetes caused by type B insulin resistance due to development of insulin receptor autoantibodies during treatment of hepatitis C with interferon-α and ribavirin. Methods: Clinical and laboratory findings in the case are presented. The literature on type B insulin resistance and interferon-induced autoimmunity is reviewed. Results: A 55-year-old African American man with hepatitis C was treated with interferon and ribavirin. Eight months later, he presented with rapid onset of hyperglycemia, profound weakness, and weight loss. Severe hyperglycemia persisted despite insulin infusion rates as high as 125 U/h. The presence of insulin receptor autoantibodies was confirmed by immunoprecipitation of recombinant human insulin receptor with patient serum. Assays for autoantibodies to islet cell antigens and glutamic acid decarboxylase were negative. The interferon and ribavirin were discontinued. His insulin requirement spontaneously declined to low levels over a 6-month period. Two years after discharge of the patient, insulin receptor autoantibodies could no longer be demonstrated in his serum. He remains euglycemic and is no longer taking insulin. Conclusion: This case demonstrates that type B insulin resistance can occur as a complication of interferon- a therapy. To our knowledge, this is the first reported case in the United States of type B insulin resistance with development of insulin receptor autoantibodies during treatment with interferon-a. (Endocr Pract. 2009;15: 153-157).",
author = "Daniel, {Amanda L.} and Houlihan, {Josetta L.} and Janice Blum and Walsh, {James P.}",
year = "2009",
month = "3",
language = "English",
volume = "15",
pages = "153--157",
journal = "Endocrine Practice",
issn = "1530-891X",
publisher = "American Association of Clinical Endocrinology",
number = "2",

}

TY - JOUR

T1 - Type B insulin resistance developing during interferon-α therapy

AU - Daniel, Amanda L.

AU - Houlihan, Josetta L.

AU - Blum, Janice

AU - Walsh, James P.

PY - 2009/3

Y1 - 2009/3

N2 - Objective: To report a rare case of diabetes caused by type B insulin resistance due to development of insulin receptor autoantibodies during treatment of hepatitis C with interferon-α and ribavirin. Methods: Clinical and laboratory findings in the case are presented. The literature on type B insulin resistance and interferon-induced autoimmunity is reviewed. Results: A 55-year-old African American man with hepatitis C was treated with interferon and ribavirin. Eight months later, he presented with rapid onset of hyperglycemia, profound weakness, and weight loss. Severe hyperglycemia persisted despite insulin infusion rates as high as 125 U/h. The presence of insulin receptor autoantibodies was confirmed by immunoprecipitation of recombinant human insulin receptor with patient serum. Assays for autoantibodies to islet cell antigens and glutamic acid decarboxylase were negative. The interferon and ribavirin were discontinued. His insulin requirement spontaneously declined to low levels over a 6-month period. Two years after discharge of the patient, insulin receptor autoantibodies could no longer be demonstrated in his serum. He remains euglycemic and is no longer taking insulin. Conclusion: This case demonstrates that type B insulin resistance can occur as a complication of interferon- a therapy. To our knowledge, this is the first reported case in the United States of type B insulin resistance with development of insulin receptor autoantibodies during treatment with interferon-a. (Endocr Pract. 2009;15: 153-157).

AB - Objective: To report a rare case of diabetes caused by type B insulin resistance due to development of insulin receptor autoantibodies during treatment of hepatitis C with interferon-α and ribavirin. Methods: Clinical and laboratory findings in the case are presented. The literature on type B insulin resistance and interferon-induced autoimmunity is reviewed. Results: A 55-year-old African American man with hepatitis C was treated with interferon and ribavirin. Eight months later, he presented with rapid onset of hyperglycemia, profound weakness, and weight loss. Severe hyperglycemia persisted despite insulin infusion rates as high as 125 U/h. The presence of insulin receptor autoantibodies was confirmed by immunoprecipitation of recombinant human insulin receptor with patient serum. Assays for autoantibodies to islet cell antigens and glutamic acid decarboxylase were negative. The interferon and ribavirin were discontinued. His insulin requirement spontaneously declined to low levels over a 6-month period. Two years after discharge of the patient, insulin receptor autoantibodies could no longer be demonstrated in his serum. He remains euglycemic and is no longer taking insulin. Conclusion: This case demonstrates that type B insulin resistance can occur as a complication of interferon- a therapy. To our knowledge, this is the first reported case in the United States of type B insulin resistance with development of insulin receptor autoantibodies during treatment with interferon-a. (Endocr Pract. 2009;15: 153-157).

UR - http://www.scopus.com/inward/record.url?scp=67549093932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67549093932&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 153

EP - 157

JO - Endocrine Practice

JF - Endocrine Practice

SN - 1530-891X

IS - 2

ER -